Acadian Asset Management
ARCT icon

Acadian Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Acadian Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$880K Sell
131,451
-149,049
-53% -$1.17M ﹤0.01% 1300
2026
Q1 		$2.16M Sell
280,500
-147,394
-34% -$1.08M ﹤0.01% 935
2025
Q4 		$2.62M Buy
427,894
+191,549
+81% +$2.07M ﹤0.01% 843
2025
Q3 		$4.35M Buy
236,345
+98,443
+71% +$1.58M 0.01% 680
2025
Q2 		$1.79M Buy
137,902
+71,560
+108% +$846K ﹤0.01% 857
2025
Q1 		$701K Buy
+66,342
New +$1.05M ﹤0.01% 1003
2024
Q4 		– Sell
-10,171
Closed -$235K – 1627
2024
Q3 		$235K Buy
+10,171
New +$218K ﹤0.01% 1304
2023
Q3 		– Sell
-19,181
Closed -$548K – 1639
2023
Q2 		$548K Buy
19,181
+19,081
+19,081% +$519K ﹤0.01% 1033
2023
Q1 		$2K Buy
+100
New +$1.79K ﹤0.01% 1707
2022
Q4 		– Sell
-75,047
Closed -$1.11M – 1766
2022
Q3 		$1.11M Buy
+75,047
New +$1.26M 0.01% 777
2020
Q3 		– Sell
-55,642
Closed -$2.6M – 2161
2020
Q2 		$2.6M Buy
55,642
+24,436
+78% +$842K 0.01% 663
2020
Q1 		$424K Buy
31,206
+16,219
+108% +$208K ﹤0.01% 1002
2019
Q4 		$163K Buy
+14,987
New +$157K ﹤0.01% 1333
2019
Q2 		– Sell
-5,562
Closed -$38K – 1774
2019
Q1 		$38K Hold
5,562
– – ﹤0.01% 1726
2018
Q4 		$25K Buy
5,562
+100
+2% +$615 ﹤0.01% 1530
2018
Q3 		$48K Buy
+5,462
New +$45.5K ﹤0.01% 1368
2018
Q2 		– Sell
-9,746
Closed -$54K – 1689
2018
Q1 		$54K Buy
+9,746
New +$67.2K ﹤0.01% 1339
2016
Q3 		– Sell
-1,219
Closed -$38K – 1407
2016
Q2 		$38K Buy
+1,219
New +$38.4K ﹤0.01% 1112
2014
Q1 		– Sell
-1,784
Closed -$224K – 956
2013
Q4 		$224K Sell
1,784
-292
-14% -$36.7K ﹤0.01% 794
2013
Q3 		$263K Buy
+2,076
New +$185K ﹤0.01% 722

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management's ARCT Position: Q2 2026 in Review

Acadian Asset Management reduced its Arcturus Therapeutics (ARCT) stake by 53% in Q2 2026, selling an estimated $1.17M and leaving 131,451 shares worth $880K. The position accounts for ﹤0.01% of the portfolio, ranked #1300.

Acadian Asset Management first reported a position in ARCT in Q3 2013 and has held it in 20 quarters since. The position peaked at $4.35M in Q3 2025. 125 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Acadian Asset Management held 131,451 shares of Arcturus Therapeutics worth $880K as of Q2 2026.
  • Acadian Asset Management sold 149,049 Arcturus Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Arcturus Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1300 holding.
  • Acadian Asset Management first reported a position in Arcturus Therapeutics in Q3 2013 and has held it in 20 quarters since.
  • Acadian Asset Management's Arcturus Therapeutics position peaked at $4.35M in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.